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Model-independent methodIn this work, the dissolution profiles of nine meloxicam tablet brands marketed in Argentina have been
evaluated. As meloxicam is a Class 2 Biopharmaceutical Classification System (BSC) drug, interchange-
ability between commercial products must be demonstrated through in vivo bioequivalence studies.
However, in our country, such studies remain to be performed.
Dissolution studies have been performed according to USP 38 and evaluated by fitting experimental
data to the zero and first-order, the Hixson-Crowell, the Higuchi, and the Weibull model-dependent
methods. To test the pertinence of these release models, the Akaike Information Criteria (AIC) were used.
All brands satisfied the dissolution profiles (phosphate buffer, pH 7.5) established in the USP. The com-
parison between the dissolution profiles was carried out by model-dependent and model-independent
methods. The Weibull model provided the best kinetic curve adjustment. Brands I, II, IV and VI had
the best fitting, with the maximum determination coefficient and the smallest AIC values. Model-
independent methods included ratio test and the fit factors. The Dissolution Efficiency (DE) and Mean
Dissolution Time (MDT) were analysed with ANOVA and the DGC method. In both cases, brand I did
not show similarity with the rest of the brands. Using fit factors, only brands I, II and V were similar
to each other.
Significant differences were found among the in vitro dissolution profiles of meloxicam tablets belong-
ing to the nine brands. As meloxicam is a class 2 BCS drug, interchangeability between commercial prod-
ucts must be demonstrated through in vivo bioequivalence studies. However, in Argentina, such studies
remain to be performed. Our results demonstrate that caution must be exercised as regards interchange-
ability of generic products.
 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is known that low water solubility causes a decrease in the
release rate of a drug. Thus, the formulation of oral delivery forms
of these drugs is a permanent challenge in the pharmaceutical
industry. In many cases, the dissolution rate of these drugs is a
limiting factor affecting the therapeutic activity. To enhance disso-
lution several techniques have been developed, such as salt forma-
tion, and the development of inclusion complexes and pro-drugs
(Jafar et al., 2010; Noolkar et al., 2013).Three categories of dissolution test specifications for immediate
release products are described in the guide provided by the Centre
for Drug Evaluation and Research at the Food and Drug Administra-
tion (Food and Drug Administration, 1997): (a) single-point speci-
fications, (b) two-points specifications and (c) dissolution profile
comparison. Although this point estimate approach is suitable for
drug products containing API with high solubility-high permeabil-
ity, it may not be adequate for low solubility drugs or for products
with modified release characteristics. According to the guide: ‘‘for
highly soluble and rapidly dissolving drug products (BCS classes 1
and 3), a single-point dissolution test specification of 85% (Q = 80%)
in 60 min or less is sufficient as a routine quality control test for
batch-to-batch uniformity”. For class 2 BSC APIs, it is recommended
that a two-point dissolution specification be established, one at 15
min and the other at 30, 45, or 60 min, in order to ensure 85% dis-
solution (Food and Drug Administration,1997).
Although weight, hardness, content uniformity, friability and
disintegration are tests often employed for the analysis of an
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quantitation of the API, the determination of impurities and the
dissolution test (Al Ameri et al., 2012). Once the dissolution spec-
ifications are set for a new drug, based on availability studies, such
specifications become official for the development of all subse-
quent drug products having the same active ingredients. According
to good laboratory practices, dissolution is considered one of the
most important tests that is to be performed on a solid pharmaceu-
tical dosage form (Al Ameri et al., 2012). This test is also used to
control stability of the drug product and batch-to-batch consis-
tency (Food and Drug Administration, 1997; Administración
Nacional de Medicamentos, Alimentos y Tecnología Médica, 1999).
Economic reasons account for the widespread use of generic
medicines. Thus, in vivo bioequivalence studies are necessary to
ensure the existence of therapeutic equivalence between the gen-
eric medicine and the original drug product containing the same
active drug, except when the drug is highly soluble and highly per-
meable, i.e., class I BCS compounds.
In vitro dissolution profiles can be compared by three groups of
methods: (A) methods based on analysis of variance, (B) model-
dependent methods, (C) model-independent methods. Dissolution
data can either be analysed in their crude form or they can be
transformed using simple ANOVA-based methods. The ANOVA is
a useful method to detect differences between the profiles in level
and shape (Polli et al., 1997; Yuksel et al., 2000; Costa and Souza
Lobo, 2001; Adams et al., 2001; LeBlond et al., 2016).
Model-dependent methods are based on an appropriate curve
fitting procedure: the zero and first-order, the Hixson-Crowell,
the Higuchi, the quadratic, the Weinbull, the Gompertz and the
logistic (Yuksel et al., 2000; Costa et al., 2003; Khan et al., 2013).
Model-dependent methods explore the mathematical equations
governing the liberation profile as a function of certain parameters
related to the pharmaceutical dosage form. These models allow an
easy quantitative interpretation of data. These methods are always
applied in the formulation-development stage.
Model-independent methods generate a single value from a dis-
solution profile, thus allowing data to be compared directly.
Model-independent methods include fit factors and ratio tests.
Ratio tests determine, at the same sampling time, the percentage
of drug dissolved, the mean dissolution time (MDT) and the disso-
lution efficiency percentage (DE) of the test formulation in relation
with a reference formulation (Khan and Rhodes, 1972; Aguilar
et al., 2008). Fit factors are known as the difference factor (f1)
and the similarity factor (f2) (The United States Pharmacopeia,
2015a; Moore and Flanner, 1996; European Medicines Agency,
2010; Administración Nacional de Medicamentos, Alimentos y
Tecnología Médica, 2016).
A class 2 BCS compound is permeable but relatively insoluble.
Various techniques have been developed to improve the dissolu-
tion rate of class 2 compounds, including micronization, inclusion
complex formation, complexation, conversion into amorphous
state and solid dispersion (Jafar et al., 2010).
According to the FDA, EMA and WHO, the comparison of phar-
maceutical products containing class 2 BCS API must be performed
by in vivo bioequivalence studies.
Meloxicam, 4-hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-
1,2-benzothiazine-3-carboxamide-1,1-dioxide is an oxicam deriva-
tive with non-steroidal anti-inflammatory properties whose poor
water solubility limits its therapeutic efficacy. According to its sol-
ubility and permeability, meloxicam belongs to class 2 BCS (Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, NICHD, and the U.S. Food and Drug Administration,
2017; Pappich and Martinez, 2015; Sugihara et al., 2015).
The aim of the present study was to evaluate and compare the
dissolution profile of nine commercial products containing
Meloxicam 15 mg. marketed in Argentina, on the basis of theirin vitro dissolution characteristics using the dissolution conditions
in the USP monograph for Meloxicam Tablets (The United States
Pharmacopeia, 2015b). Our results demonstrate that caution must
be exercised as regards interchangeability of generic products.
2. Materials and methods
2.1. Reagents
Analytical grade potassium dihydrogen phosphate (Biopack,
Argentina) and sodium hydroxide (Anedra, Argentina) were used.
Meloxicam was purchased in Unifarma (Argentina), with 99.9%
purity, as calculated with reference to the dried substance (India).
2.2. Materials
Nine commercial brand tablets containing 15 mg meloxicam
were purchased from pharmacies in Buenos Aires (Argentina). All
tests were performed before the product expiration dates, which
were similar among brands.
2.3. Apparatus and procedure
All dissolution studies were performed using USP Apparatus 2
(The United States Pharmacopeia, 2015b) in a Vankel, VK 7010
(Varian Inc., USA) manual-sampling dissolution bath. The meloxi-
cam tablets dissolution test was performed at 75 ± 1 rpm in phos-
phate buffer pH = 7.5. The acceptance criterion was Q = 70% of the
labeled amount of meloxicam released in 30 min.
The dissolution medium volume was 900 ml. In all experiments,
10 ml sample aliquots were withdrawn at 5, 15, 30, 45 and 60 min
using micropipettes, without medium replacement. The with-
drawn amounts were adjusted in the calculations. All samples
were filtered through 10.0 mm filter paper (Whatman 91), which
was properly validated with the standard solution comparing its
performance with that obtained with membrane filters. The drug
amount dissolved was determined spectrophotometrically in a
Cary 1E Varian UV–VIS spectrophotometer (Victoria, Australia) at
362 nm. To prove peak purity, the second order derivative UV spec-
tra was recorded against dissolution medium as reference solution.
This procedure was performed with each product.
Twelve tablets of each preparation were studied to obtain sta-
tistically significant results.
2.4. Model-dependent methods
Five model-dependent approaches were used to compare the
meloxicam dissolution profiles. The model-dependent approaches
included the zero order, the first order, the Hixson-Crowell, the
Higuchi and the Weibull models.
2.4.1. Zero order kinetics
The drug dissolution from pharmaceutical dosage forms that do
not disaggregate and deliver the API slowly (assuming that the area
is not modified and that no equilibrium conditions are reached)
can be represented by the following equation:
Qt ¼ Q0 þ K0t ð1Þ
where Q0 is the initial amount of drug in the pharmaceutical dosage
form, Qt is the amount of drug in the pharmaceutical dosage form at
time t and K0t is the proportionality constant.
2.4.2. First order kinetics
The amount of API delivered from pharmaceutical dosage forms
following this dissolution profile are delivered with a rate that is
comparable to the amount of API remaining within, in such way
Table 1
Formulation compositions.
Brand Other ingredients Appearance
I Sodium citrate, lactose, microcrystalline
cellulose, povidone, colloidal silicon
dioxide, insoluble povidone, magnesium
stearate
Yellow, circular, with
indented line in centre
II Lactose, microcrystalline cellulose,
povidone, insoluble povidone, colloidal
silicon dioxide, sodium citrate, sunset
yellow aluminum lake, magnesium
stearate
Orange, circular, with
indented line in centre
III Lactose monohydrate, sodium citrate,
povidone, magnesium stearate, colloidal
silicon dioxide, polyethilene glycol 1500,
microcrystalline cellulose, crospovidone
Yellow, circular, with
indented line in centre
IV Lactose monohydrate, microcrystalline
cellulose, crospovidone, colloidal silicon
dioxide, sodium citrate dehydrate,
magnesium stearate, iron (III) oxide
yellow
Orange, circular, with
indented line in centre
V Lactose monohydrate, microcrystalline
cellulose, sodium citrate trihydrate,
povidone K30, colloidal silicon dioxide,
crospovidone, magnesium stearate
Yellow, circular, with
indented line in centre
VI Cellactose, crospovidone, povidone K30,
sodium citrate, colloidal silicon dioxide,
magnesium stearate
Yellow, circular, with
indented line in centre
VII Cellactose, sodium croscarmellose,
colloidal silicon dioxide, sodium citrate
dihydrate, magnesium stearate
Yellow, circular, with
indented line in centre
VIII Sodium citrate, lactose, microcrystalline
cellulose, povidone, iron (III) oxide red,
colloidal silicon dioxide, crospovidone,
magnesium stearate
Orange, circular, with
indented line in centre
IX Sodium croscarmellose, sodium lauryl
sulfate, cellactose 80, reticulated
polyvinylpirrolidone, colloidal silicon
dioxide, magnesium stearate, sodium
citrate
Yellow, circular, with
indented line in centre.
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order dissolutions can be represented by the following equation:
lnQt ¼ lnQ0 þ K0t ð2ÞFig. 1. Dissolution profileswhere Q0 is the initial amount of API in the pharmaceutical dosage
form, Qt is the amount of API in the pharmaceutical dosage form at
time t and K0 is the proportionality constant
2.4.3. Hixson-Crowell model
The Hixson-Crowell model assumes that the particle normal
area is comparable to the cubic root of its volume. The following
equation represents the dissolution profile:
Q1=30 þ Q1=3t ¼ Kd t ð3Þ
where Q0 is the initial amount of API in the pharmaceutical dosage
form, Qt is the amount of API in the pharmaceutical dosage form at
time t and Kd is the dissolution constant.
2.4.4. Higuchi model
The Higuchi equation is a ‘‘square root of time” release kinetics.
This kinetic model gives good experimental fitting data in API dis-
solution processes formulated as modified liberation systems or






where Kd is the dissolution constant.
2.4.5. Weibull model
The Weibull function is a mathematical model lacking physico-
chemical fundament and can be used to study the dissolution rate.





¼ b lnðt  t0Þ  blntd ð5Þ
where Q is the amount of API dissolved at time t, Q1 is the amount
of API dissolved at time infinite, also called ‘‘total dissolution”, t0 is
the lag time and td is the time interval necessary to dissolve or
release 63.2% of the API present in the pharmaceutical dosage form.
The shape parameter b is obtained from the slope.
To test the pertinence of the release models employed, the
Akaike Information Criteria (AIC) (Aguilar et al., 2008) were used.
The AIC are a measure of the best fit based on maximum probability.of meloxicam tablets.
Table 2
Dissolution data and descriptive statistics of nine meloxicam tablet brands.
Time (min) Brand mean% RSD Lower limit Upper limit
I 32.3 30.4 14.0 48.4
II 24.2 8.6 20.8 27.8
III 60.3 9.8 49.4 67.7
IV 59.9 9.8 51.7 66.8
5 V 28.7 8.3 25.2 32.0
VI 69.8 13.4 49.7 82.7
VII 66.7 10.1 56.5 78.3
VIII 78.8 1.9 76.0 81.2
IX 59.2 2.6 56.7 62.8
I 66.9 7.5 58.6 74.0
II 64.2 8.6 55.0 74.2
III 88.7 6.5 77.0 96.6
IV 83.0 5.4 77.2 89.2
15 V 74.0 2.5 71.4 77.2
VI 86.9 7.0 79.3 94.8
VII 89.8 8.7 84.9 113.3
VIII 97.8 2.5 95.3 102.5
IX 85.0 4.6 78.1 92.9
I 83.2 5.7 74.4 88.7
II 79.5 8.3 68.8 89.0
III 98.5 7.0 83.9 109.7
IV 93.4 2.8 88.9 98.2
30 V 92.2 2.9 88.6 96.7
VI 91.9 4.3 87.0 97.8
VII 99.7 3.6 95.8 107.4
VIII 102.2 1.7 99.7 105.4
IX 99.9 3.0 92.4 105.6
I 89.6 5.7 80.8 97.0
II 95.0 4.7 85.8 102.8
III 100.1 6.9 88.0 112.4
IV 97.9 2.4 93.3 102.4
45 V 93.9 1.4 91.6 96.1
VI 93.2 5.5 85.3 102.0
VII 98.0 3.6 94.4 105.6
VIII 102.2 2.7 99.4 108.1
IX 105.0 4.0 98.7 111.0
I 97.0 3.1 90.0 102.0
II 98.8 5.2 87.1 107.0
III 101.5 6.2 89.7 114.1
IV 98.5 4.3 89.6 107.1
60 V 95.3 2.0 92.9 98.8
VI 96.0 5.9 89.2 109.5
VII 98.4 5.8 91.4 106.4
VIII 103.0 0.7 101.8 104.4
IX 105.8 2.6 100.0 110.4
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AIC value is considered the best fit. The AIC is only applicable when
specimens with equal weighting scheme are compared.Table 3
Parameters of the mathematical models and descriptive statistics for the dissolution data
Brands
Model Statistics I II III I
Zero Order r2 0.8257 0.8414 0.6774 0
k 0.1385 0.1644 0.0842 0
AIC 12.38 13.53 11.47 9
First Order r2 0.9553 0.9667 0.8080 0
k 0.0268 0.0319 0.0244 0
AIC 9.59 9.35 2.40 
Hixson-Crowell r2 0.9195 0.9361 0.7647 0
k 0.0151 0.0179 0.0121 0
AIC 14.16 13.71 10.15 
Higuchi r2 0.9243 0.9342 0.8102 0
k 1.4778 1.7464 0.9283 0
AIC 8.22 9.13 8.82 5
Weibull r2 0.9985 0.9955 0.9896 0
Td 13.25 14.93 2.53 3
b 0.4265 0.5320 0.2763 0
AIC 25.20 17.60 19.95 AIC ¼ n lnðWSSRÞ þ 2p ð6Þ
where n is the number of dissolution data points, p is the number of
parameters of themodel, WSSR is the weight sum of square of residues.
2.5. Model-independent methods
2.5.1. Fit factors
Moore and Flanner (Moore and Flanner, 1996) have developed a
simple model for independent approximation using fit factors. Fit
factors are the difference factor f1, and the similarity factor f2.
These fit factors contrast the difference between the percent API
dissolved per unit time of a test with that of a reference formula-
tion. Fit factors have been accepted by FDA Centre for Drug Evalu-
ation and Research (CDER) (Food and Drug Administration, 1997)
and the similarity factor has also been adopted by the European
Medicines Agency (EMA) Committee for Medicinal Products for
Human Use (CHMP) (European Medicines Agency, 2010) and
World Health Organization (WHO) (World Health Organization,
2006) as a rating criterion of similarity between two in vitro disso-
lution profiles. In Argentina, regulations establish that changes in
the post marketing stage as regards dissolution profiles must be
evaluated using the similarity factor f2 (Administración Nacional
de Medicamentos, Alimentos y Tecnología Médica, 2009).
The fit factors are denoted f1 (difference factor) and f2 (similar-
ity factor) and are defined by Eqs. (7) and (8).
f1 ¼
P jRt  TtjP
Rt
 
 100 where t ¼ 1 to n ð7Þ











(7) Difference factor (8) Similarity factor
where n is the number of dissolution sampling times, and Rt and
Tt are the individual or mean percent dissolved at each time point,
t, for the reference and test dissolution profiles, respectively. The
parameter f1, whose values range from 0 to 15, and f2, whose values
range from 50 to 100, are used to define equivalence of two disso-
lution profiles, which means an average difference 10% at each
sampling time.
2.5.2. Dissolution efficiency
This concept has been presented by Khan and Rhodes in 1972
(Khan and Rhodes (1972)). For each sample, the percentage.
V V VI VII VIII IX
.7601 0.6720 0.7272 0.5990 0.5931 0.7807
.0834 0.1374 0.0529 0.0637 0.0468 0.1028
.32 16.49 5.63 10.37 7.43 10.83
.8689 0.7903 0.8205 0.6411 0.6815 0.9182
.0220 0.0268 0.0143 0.0179 0.0180 0.0350
5.69 1.28 8.17 1.18 2.03 3.68
.8352 0.7523 0.7896 0.6304 0.6507 0.8791
.0113 0.0147 0.0073 0.0090 0.0082 0.0162
13.03 7.82 15.87 9.83 11.27 11.21
.8788 0.8069 0.8464 0.7440 0.7338 0.8951
.9039 1.5180 0.5751 0.7153 0.5250 1.1102
.91 13.85 2.76 8.14 5.31 7.14
.9961 0.9745 0.9934 0.9470 0.9635 0.9866
.22 11.60 1.30 1.50 0.32 2.85
.2541 0.4749 0.1632 0.2167 0.1761 0.3306
25.68 9.97 27.51 14.00 18.03 16.86
Fig. 2. Statistical comparison of the Dissolution Efficiency (DE) among the nine commercial products. The average is indicated near the boxes. Bars indicate standard
deviation.
Fig. 3. Statistical comparison of the Mean Dissolution Time (MDT) among the nine
commercial products. The average is indicated near the boxes. Bars indicate the
standard deviation.
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area under the dissolution curve up to time t to that of the area
of the rectangle described by 100% dissolution at the same time





100 ð9Þ2.5.3. Mean dissolution time
The mean dissolution time is determined from the accumula-




where ti is an intermediate time of the intervals of sampling time,
DQi is the amount of API dissolved in every interval of t and Q1
is the maximum of API dissolved.
Results of DE and MDT corresponding to the different meloxi-
cam tablet brands were compared by one-way analysis of variance
(ANOVA). The analysis was performed with the Infostat 2008 sta-
tistical package (Di Rienzo et al., 2008). After this analysis, a
multiple-comparisons method (DGC) was applied (Di Rienzo
et al., 2002).3. Results and discussion
In vitro dissolution testing is a fundamental analytical method-
ology in the pharmaceutical industry. This methodology allows
quality assurance of solid pharmaceutical forms for oral adminis-
tration. The lot-to-lot quality assurance fosters the development
of new formulations, guarantee quality homogeneity and ensure
an acceptable API performance even after being modified. If all
these requirements are met, the formulation optimization during
the development phase is favoured, and stability studies and man-
ufacturing process quality control can be carried out (Adams et al.,
2001; Dressman et al., 1998; Ferraz et al., 2007).
Table 1 summarises the characteristics of the nine products.
Brand I was taken as the reference product.
The dissolution test for meloxicam tablets described in the USP
(The United States Pharmacopeia, 2015b) indicates that no less
than 70% (Q + 5%) of the API should be dissolved in 30 min. Table 2
summarises the mean percent dissolved at each time point, the rel-
ative standard deviation (RSD), and the upper and lower limits. As
shown in Table 2, all Brands fulfilled the USP specifications.
Dissolution curves indicated that the analysed products pre-
sented different dissolution profiles (Fig. 1). As meloxicam is a class
2 BCS drug, the dissolution test may be formulation-dependent,
and the decision related to generics must be made based on the
in vivo bioequivalence studies.
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were evaluated by fitting experimental data to the zero and first-
order, the Hixson-Crowell, the Higuchi, and the Weibull models.
In Table 3, the following parameters are presented: dissolution
constants (k) and the determination constant (r2), for zero and first
order, Hixson-Crowell and Higuchi models, and the shape parame-
ter b, the determination constant (r2) and Td which is the time
interval necessary to dissolve or release 63.2% of the drug present
in the pharmaceutical dosage form, for the Weibull model. No sig-
nificant variations were found among all b values (b < 1). The Wei-
bull model provided the best adjustment curve for the nine brands,
with the higher determination coefficients (r2) and smallest AIC
values for all the brands tested (bold print indicating the best fits).
The determination of DE and MDT values are useful methods to
reduce each curve to a single number, which may be referred to the
dissolution rate constant (Figs. 2 and 3). Statistical differences were
found among the brands analysed (Tables 4a,4b., and 5a.,5b.). The
DGC test indicated that brands III, IV, VI and IX were similar,
whereas brand VII was similar to brand VIII. MDT values for brands
III, IV and VI were found to be similar to each other, whereas brand
VII was similar to brand VIII. In both cases, brand I was not found to
be similar to any other.
Fit factors are important quantitative parameters recom-
mended by the FDA to compare dissolution profiles (Food and
Drug Administration, 1997). The results obtained with each brand
using brand I as reference are shown in Table 6. The similarity fac-
tor f2 is more sensitive in finding dissimilarities between dissolu-
tion curves than the difference factor f1, and the fit factor values
are dependent on the number of sampling time point selected.Table 4a
Variance analysis (ANOVA) of DE Values for the nine pharmaceutical products.
Variation source Square sum Degree
Between treatments 3733.05 8
Within treatments 635.68 99
Total 4368.73 107
Fcritical = 1.890.
a Significant for P > 0.05.
Table 4b
DGC test of DE values for the nine pharmaceutical products.
Test:DGC Alfa = 0.05 PCALT = 2.1382
Error: 6.4210 df: 99
Brands Average n E.E.
II 73.25 12 0.73
I 75.56 12 0.73
V 81.26 12 0.73
IX 84.64 12 0.73
IV 86.24 12 0.73
VI 86.77 12 0.73
III 87.03 12 0.73
VII 90.25 12 0.73
VIII 91.45 12 0.73
Table 5a
Variance analysis (ANOVA) of MDT values for the nine Pharmaceutical products.
Variation source Square sum Degree
Between treatments 1885.17 8
Within treatments 299.49 99
Total 2184.66 107
Fcritical = 2.033.
a Significant for P > 0.05.According to the FDA, f1 values less that 15 and f2 values greater
than 50 should ensure equivalence between the dissolution curves,
indicating an average difference of no more than 10% at the sample
time points. According to this guideline, the dissolution curves cor-
responding to brand II and brand V would be similar to that
obtained with the reference formulation.4. Conclusions
This study found variations in the dissolution profiles of meloxi-
cam tablets commercially available in Argentina. The dissolution
profiles obtained with the analysed products were found to be
quite different from each other, thus demonstrating that the
results obtained with the dissolution test are formulation-
dependent. All brands fulfilled the specifications of the dissolution
test established by the USP 38.
The Weibull model kinetic curve rendered the best adjustment.
The best fittings were obtained with brands I, II, IV and VI, with
maximum determination coefficients and smallest AIC values.
The ANOVA and DGC tests applied to DE and MDT values
demonstrated that brand I was not similar to any other.
If fit factors are considered, only brands I, II and V were similar.
In conclusion, significant differences were observed between
the in vitro dissolution profiles of meloxicam tablets of different
commercial preparations. As meloxicam is a class II BCS drug,
interchangeability between commercial products must be demon-
strated with in vivo bioequivalence studies, which remain to be
















DGC test of MDT values for the nine Pharmaceutical products.
Test:DGC Alfa = 0.05 PCALT = 1.4676
Error: 3.0251 df: 99
Brands Average n E.E.
VIII 8.35 12 0.50 A
VII 9.37 12 0.50 A
III 11.61 12 0.50 B
VI 11.62 12 0.50 B
IV 12.13 12 0.50 B
IX 13.31 12 0.50 C
V 16.05 12 0.50 D
I 19.61 12 0.50 E
II 21.31 12 0.50 F
Table 6
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